186 related articles for article (PubMed ID: 38057405)
1. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer.
Ye Y; Zhang S; Jiang Y; Huang Y; Wang G; Zhang M; Gui Z; Wu Y; Bian G; Li P; Zhang M
Sci Rep; 2023 Dec; 13(1):21565. PubMed ID: 38057405
[TBL] [Abstract][Full Text] [Related]
2. Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in colon adenocarcinoma.
Zheng L; Zhang J; Ye Y; Shi Z; Huang Y; Zhang M; Gui Z; Li P; Qin H; Sun W; Zhang M
Aging (Albany NY); 2023 Sep; 15(18):9521-9543. PubMed ID: 37724904
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a cancer-associated fibroblasts-related scoring system to predict prognosis and immune landscape in hepatocellular carcinoma through integrated analysis of single-cell and bulk RNA-sequencing.
Bao L; Zhang X; Wang W; Jiang B
Aging (Albany NY); 2023 Oct; 15(20):11092-11113. PubMed ID: 37857017
[TBL] [Abstract][Full Text] [Related]
4. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
5. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Wu M; Gu S; Xu S; Wu Y; Wang Y
J Ovarian Res; 2023 Apr; 16(1):86. PubMed ID: 37120633
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
[TBL] [Abstract][Full Text] [Related]
8. Assessing of programmed cell death gene signature for predicting ovarian cancer prognosis and treatment response.
Lian X; Liu B; Wang C; Wang S; Zhuang Y; Li X
Front Endocrinol (Lausanne); 2023; 14():1182776. PubMed ID: 37342266
[TBL] [Abstract][Full Text] [Related]
9. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Xu Y; Wang Y
J Ovarian Res; 2023 Sep; 16(1):196. PubMed ID: 37730669
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
11. Immune Subtype Profiling and Establishment of Prognostic Immune-Related lncRNA Pairs in Human Ovarian Cancer.
Wang X; Wang J; Yu M
Comput Math Methods Med; 2022; 2022():8338137. PubMed ID: 35578596
[TBL] [Abstract][Full Text] [Related]
12. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors.
Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF
J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of regulatory T-cells-related scoring system for predicting the prognosis, immune microenvironment and therapeutic response in hepatocellular carcinoma.
Jiang B; Ye X; Wang W; He J; Zhang S; Zhang S; Bao L; Xu X
Aging (Albany NY); 2024 Mar; 16(6):5288-5310. PubMed ID: 38461439
[TBL] [Abstract][Full Text] [Related]
14. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
Front Immunol; 2022; 13():992060. PubMed ID: 36311733
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
17. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
18. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9.
Luo X; Wang Y; Zhang H; Chen G; Sheng J; Tian X; Xue R; Wang Y
Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
